Key Takeaways
- Shares of Zoetis declined 20% to $88.94 during Thursday’s trading, marking the session’s largest S&P 500 decline
- First-quarter earnings per share reached $1.53, falling short of the $1.60 analyst projection; sales totaled $2.26B versus the $2.3B forecast
- Management reduced annual EPS projections to a range of $6.85–$7.00 from the previous $7.00–$7.10 outlook
- Leadership pointed to heightened consumer cost consciousness and declining veterinary appointments as primary challenges
- Analysts at Stifel noted performance appears even weaker after accounting for a $100M revenue increase from fiscal calendar adjustment
Shares of Zoetis (ZTS) plummeted 20% to $88.94 during Thursday’s session, positioning the animal health company as the S&P 500’s weakest performer for the day. Data from Dow Jones Market Data indicates the stock is heading toward its lowest closing price in more than seven years, with year-to-date losses reaching 29%.
The sharp decline followed the company’s release of first-quarter financial results that fell below analyst expectations across key metrics.
The company reported quarterly earnings of $1.53 per share, representing growth from $1.48 in the same period last year while missing the Street’s $1.60 target. Sales increased 3% from the prior year to reach $2.26 billion, falling beneath the $2.3 billion consensus estimate compiled by FactSet.
Chief Executive Kristin Peck acknowledged the quarter unfolded amid more challenging conditions than management had anticipated. Consumer spending on pets contracted, resulting in reduced veterinary appointments and diminished appetite for higher-priced offerings.
Domestic revenue contracted approximately 8% compared to the year-ago period, totaling $1.1 billion. Sales of companion animal products in the United States fell roughly 11%, pressured by weakening demand and competitive dynamics.
Overseas Markets Provided Partial Offset
Revenue from international operations expanded 17% year-over-year to $1.1 billion, supported by a 10% increase in companion animal product sales. The parasiticides product line served as a primary growth catalyst in these markets.
That said, the international figure incorporated approximately $100 million in revenue shifted forward due to a change in fiscal reporting alignment. The company removed a one-month reporting delay for international divisions, creating a temporary boost to Q1 overseas results that will remain a one-time occurrence.
Wall Street Analysts Highlight Underlying Weakness
Jonathan Block of Stifel, along with his research team, characterized the Q1 report as appearing even weaker upon closer examination. After removing the $100 million benefit from the reporting realignment, organic operational revenue growth landed significantly below consensus projections.
Block’s analysis emphasized substantial softness in the companion animal business as an area of particular concern.
In response, Zoetis reduced its full-year 2026 financial targets. The company now projects adjusted earnings per share in a range of $6.85 to $7.00, down from the earlier guidance of $7.00 to $7.10. Analyst consensus had been centered at $7.03.
Management also trimmed annual revenue expectations to between $9.68 billion and $9.96 billion, compared with the previous range of $9.825 billion to $10.025 billion. Wall Street estimates had clustered around $9.89 billion.
Peck stated the organization is implementing “decisive action to sharpen commercial execution, unlock revenue, and continue to drive disciplined cost management.”
The stock’s dramatic single-session retreat leaves ZTS trading at price levels last observed in early 2019.
The adjusted earnings figure of $1.53 represented approximately 9% growth versus the prior year, yet remained $0.09 below analyst projections.
Thursday’s decline extends the year-to-date loss to 29%, representing a challenging period for an equity previously viewed as a reliable performer within the healthcare sector.
